Burney Co. Sells 1,041 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Burney Co. trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 10.7% during the fourth quarter, HoldingsChannel reports. The firm owned 8,709 shares of the company’s stock after selling 1,041 shares during the quarter. Burney Co.’s holdings in Prestige Consumer Healthcare were worth $680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in PBH. Quest Partners LLC raised its position in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares during the last quarter. nVerses Capital LLC increased its stake in shares of Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank raised its position in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the period. Finally, International Assets Investment Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after buying an additional 1,138 shares in the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Up 0.4 %

PBH opened at $78.58 on Friday. The business’s fifty day simple moving average is $80.52 and its 200 day simple moving average is $74.49. Prestige Consumer Healthcare Inc. has a 52 week low of $58.22 and a 52 week high of $86.36. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock has a market cap of $3.88 billion, a PE ratio of 19.12, a P/E/G ratio of 2.08 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company’s revenue was down .9% on a year-over-year basis. During the same period in the prior year, the company earned $1.07 EPS. As a group, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider William P’pool sold 8,987 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares of the company’s stock, valued at $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. DA Davidson reiterated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. Jefferies Financial Group reissued a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, StockNews.com cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Thursday. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $85.25.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.